U.S. Building Stock News

NYSE:MH
NYSE:MHConsumer Services

McGraw Hill CEO Shift Highlights AI Push And Valuation Question

McGraw Hill (NYSE:MH) has appointed Philip Moyer as President and CEO, succeeding Simon Allen. The company is accelerating its push into AI powered education tools, gaining market share in higher education. McGraw Hill has been recognized as a leading user of AI in education and is rolling out new AI platforms with a focus on STEM. For investors watching NYSE:MH, the leadership transition comes as the company leans further into digital and AI centered offerings. The stock last closed at...
NYSE:HCI
NYSE:HCIInsurance

Is HCI Group (HCI) Still Attractive After Recent Share Price Pullback?

If you are trying to figure out whether HCI Group at around US$157.96 is still good value or already priced for perfection, you are in the right place. The stock has seen mixed returns, with a 3.3% decline over the last 7 days, a 10.5% decline over the last 30 days, a 14.1% decline year to date, a 34.6% gain over the last year and a very large 3 year return of 215.5% alongside a 192.5% return over 5 years. Recent price moves often tie back to changing views on insurance risk, regulatory...
NasdaqGS:TXG
NasdaqGS:TXGLife Sciences

Shrinking TTM Loss At 10x Genomics (TXG) Tests Bearish Earnings Narratives

10x Genomics FY 2025 earnings snapshot 10x Genomics (TXG) closed FY 2025 with Q4 revenue of US$166.0 million and a basic EPS loss of US$0.13, alongside trailing twelve month revenue of US$642.8 million and a TTM EPS loss of US$0.35 that keeps the focus squarely on the income statement. Over recent quarters the company has seen revenue range between US$149.0 million and US$172.9 million per quarter, with basic EPS swinging from a profit of US$0.28 in Q2 2025 to losses of US$0.28 in Q1, US$0.22...
NYSE:FLO
NYSE:FLOFood

Flowers Foods (FLO) Quarterly Loss And 1.6% Margin Test Bullish Earnings Narratives

Flowers Foods (FLO) just posted fourth quarter FY 2025 revenue of US$1.2b with a basic EPS loss of US$0.32, while trailing twelve month EPS came in at US$0.40 on revenue of US$5.3b. The company has seen quarterly revenue move from US$1.1b and EPS of US$0.20 in Q4 2024 to US$1.2b and EPS of US$0.19 in Q3 2025 before the latest quarterly loss, setting up a results season where investors are weighing weak reported profitability against forecasts for stronger earnings ahead. With net profit...
NYSE:IT
NYSE:ITIT

Gartner (IT) Margin Reset To 11.2% Challenges Bullish Earnings Narratives

Gartner FY 2025 earnings snapshot Gartner (IT) has wrapped up FY 2025 with Q4 revenue of US$1.8b and basic EPS of US$3.36, alongside net income of US$242.2m, setting the tone for how investors will read the year as a whole. Over recent quarters, the company has seen revenue move from US$1.5b in Q1 2025 to US$1.7b in Q2 and US$1.5b in Q3. Basic EPS has ranged from US$2.73 to US$3.36 across the year, giving you a clear view of how earnings are tracking through the cycle. With trailing net...
NasdaqGS:FHB
NasdaqGS:FHBBanks

Assessing First Hawaiian (FHB) Valuation After Recent Share Price Swings

First Hawaiian (FHB) has drawn investor attention after recent share price swings, including a small 1 day gain alongside a decline over the past week, prompting closer focus on its fundamental profile. See our latest analysis for First Hawaiian. That small 0.8% 1 day share price gain sits against a softer 7 day share price return of a 3.4% decline, while a 90 day share price return of 8.5% and 1 year total shareholder return of 1.2% point to modest, but still positive, longer term...
NYSE:QSR
NYSE:QSRHospitality

Restaurant Brands International (QSR) Margin Compression Challenges Bullish Profitability Narrative

Restaurant Brands International (NYSE:QSR) closed out FY 2025 with Q4 revenue of US$2.5b and basic EPS of US$0.69, while trailing twelve month revenue came in at US$9.4b with EPS of US$2.74. Over recent periods, revenue has moved from US$2.3b in Q4 2024 to US$2.5b in Q4 2025, and trailing EPS has shifted from US$3.20 to US$2.74, giving investors a clear read on both the top line and per share earnings trend as the year wrapped up. With a trailing net profit margin of 9.6% versus 12.1% the...
NYSE:NUS
NYSE:NUSPersonal Products

Nu Skin Enterprises (NUS) Return To Profitability Challenges Longstanding Bearish Narratives

Nu Skin Enterprises (NUS) has just reported its FY 2025 numbers with fourth quarter revenue of US$370.3 million and basic EPS of US$0.30, alongside full year trailing twelve month revenue of about US$1.6 billion and basic EPS of US$2.21. Over recent quarters, revenue has moved from US$445.6 million and basic EPS of a loss of US$0.73 in Q4 2024 to US$364.5 million with EPS of US$2.16 in Q1 2025, then US$386.1 million and US$0.43 in Q2, US$364.2 million and US$0.35 in Q3, and now US$370.3...
NYSE:BIRK
NYSE:BIRKLuxury

Birkenstock Q1 Beat, Retail Expansion And Buyback Contrast With Weak Share Price

Birkenstock Holding (NYSE:BIRK) reported robust first quarter revenue growth that exceeded its full year guidance. The company highlighted broad based strength across regions, with especially rapid expansion in APAC. Birkenstock continued to grow its global retail footprint and advanced its push toward four season footwear offerings. Management approved a new €200 million share repurchase program, signaling confidence in the brand and balance sheet. Birkenstock comes into this update with...
NasdaqCM:APPS
NasdaqCM:APPSSoftware

A Look At Digital Turbine (APPS) Valuation After Raised 2026 Guidance And Return To Quarterly Net Income

Digital Turbine (APPS) is back on investors’ radar after raising its 2026 revenue outlook to US$553 million to US$558 million and reporting third quarter results that showed a shift from a net loss to net income. See our latest analysis for Digital Turbine. The recent guidance hike and return to quarterly net income have arrived during a weak patch for the stock, with a 30 day share price return of a 20.04% decline and a 1 year total shareholder return of a 32.31% loss indicating that...
NasdaqGS:RARE
NasdaqGS:RAREBiotechs

Ultragenyx Pharmaceutical (RARE) TTM US$575 Million Loss Tests Bullish Profitability Narratives

Ultragenyx Pharmaceutical (RARE) just closed out FY 2025 with fourth quarter revenue of US$207 million and a basic EPS loss of US$1.29, while trailing twelve month revenue came in at US$673 million against a TTM basic EPS loss of US$5.83. The company has seen quarterly revenue move from US$164.9 million in Q4 2024 to US$207 million in Q4 2025, alongside quarterly basic EPS losses ranging between US$1.17 and US$1.81 over the year. For investors, the latest numbers keep the focus squarely on...
NYSE:KIM
NYSE:KIMRetail REITs

Kimco Realty Dividend Hike Meets Record Occupancy And Leasing Strength

Kimco Realty (NYSE:KIM) has approved a 4% increase to its quarterly common dividend for 2025. The company reported record overall portfolio occupancy for 2025. Kimco also recorded its highest quarterly new leasing volume in more than 10 years. Kimco Realty, a major owner of open air shopping centers, sits at the intersection of retail property and consumer spending trends. For investors following real estate income names, a 4% dividend increase from NYSE:KIM and record portfolio occupancy...
NasdaqGS:QS
NasdaqGS:QSAuto Components

QuantumScape Edges Toward Commercial Scale With Eagle Line And Licensing Shift

QuantumScape launched its Eagle Line pilot production line, targeting scalable solid state battery output. The company integrated its Cobra manufacturing process into Eagle Line to support higher volume production. QuantumScape expanded agreements with major automotive OEMs and recorded its first customer billings. PowerCo shifted to a licensing only model with QuantumScape, changing the risk and capital mix of that relationship. The company moved into non automotive markets such as data...
NYSE:CBL
NYSE:CBLRetail REITs

CBL And Associates Properties (CBL) FFO Stability Supports Bullish Narratives On Earnings Quality

CBL & Associates Properties (CBL) has just posted its FY 2025 third quarter numbers, with total revenue of US$139.3 million, basic EPS of US$2.44, and net income of US$74.3 million setting the tone for the latest update. The company has seen revenue move from US$125.1 million in Q3 FY 2024 to US$139.3 million in Q3 FY 2025, while trailing twelve month basic EPS stands at US$4.06, alongside a net profit margin of 22.3% versus 6.1% a year earlier, helped by a US$131.2 million one off gain...
NasdaqCM:RCEL
NasdaqCM:RCELBiotechs

Avita Medical (RCEL) TTM US$48.6m Loss Tests Bullish Profitability Narratives

AVITA Medical (RCEL) has just wrapped up FY 2025 with Q4 revenue of US$17.6 million, a basic EPS loss of US$0.38, and net income loss excluding extra items of US$11.6 million, giving investors a clear read on how the year finished. Over recent quarters, the company has seen revenue range from US$17.1 million to US$18.5 million, while quarterly basic EPS losses have moved between US$0.38 and US$0.53 as management pushes ahead with commercial execution and product launches. For investors, the...
NYSE:GEL
NYSE:GELOil and Gas

Genesis Energy (GEL) Returns To Quarterly Profit As Loss Narratives Face New Test

Genesis Energy (GEL) has just wrapped up FY 2025 with fourth quarter revenue of US$440.8 million and basic EPS of US$0.04, alongside net income of US$5.0 million. Trailing 12 month figures show revenue of US$1.6 billion and a basic EPS loss of US$0.73. The company has seen quarterly revenue move from US$725.6 million in Q4 2024 to US$440.8 million in Q4 2025, with EPS shifting from a loss of US$0.58 per share to a small profit of US$0.04 per share over that period. Overall, the latest print...
NasdaqGS:ZBRA
NasdaqGS:ZBRAElectronic

Zebra Technologies (ZBRA) Margin Compression To 7.8% Reinforces Bearish Profitability Narratives

Zebra Technologies (ZBRA) has wrapped up FY 2025 with fourth quarter revenue of US$1,475 million and basic EPS of US$1.39. Trailing 12 month figures show total revenue of US$5.4 billion and basic EPS of US$8.24. Over the past six reported quarters, revenue has ranged from US$1,255 million to US$1,475 million and quarterly basic EPS has moved between US$1.39 and US$3.16. This gives investors a clear view of how sales and per share earnings have tracked alongside a trailing net margin that has...
NYSE:MSC
NYSE:MSCHospitality

Studio City International Holdings (NYSE:MSC) Loss Reduction Trend Tests Bearish Narratives After Q3 Results

Studio City International Holdings (NYSE:MSC) has just reported third quarter FY 2025 results, posting revenue of US$182.5 million with a basic EPS loss of US$0.10, while trailing 12 month revenue sits at US$687.1 million against a full year EPS loss of US$0.34. Over recent quarters, revenue has moved from US$161.5 million in Q2 2024 to US$152.9 million in Q4 2024, then to US$161.7 million in Q1 2025, US$190.1 million in Q2 2025 and US$182.5 million in Q3 2025, with EPS losses ranging between...
NYSE:CPS
NYSE:CPSAuto Components

Cooper Standard (CPS) Returns To Q4 Profit And Tests Turnaround Narratives

Cooper-Standard Holdings (CPS) closed out FY 2025 with Q4 revenue of US$672.4 million and basic EPS of US$0.19, alongside net income of US$3.3 million excluding extra items. The company has seen quarterly revenue move from US$660.8 million in Q4 2024 to a range of US$667.1 million to US$706.0 million through FY 2025, while basic EPS has swung between a loss of US$0.43 in Q3 and a profit of US$0.19 in Q4, highlighting a story that focuses on how consistently those thin margins can be...
NasdaqGM:RPD
NasdaqGM:RPDSoftware

Rapid7 (RPD) Guides to 2026 Profitability After Q4 Results Is Its Margin Story Evolving?

In February 2026, Rapid7, Inc. reported its fourth-quarter 2025 results, with revenue of US$217.39 million and net income of US$3.13 million, alongside full-year 2025 revenue of US$859.79 million and net income of US$23.38 million. The company also issued 2026 guidance that points to a GAAP loss in the first quarter but a return to GAAP profitability for the full year, giving investors fresh insight into its near-term growth and margin path. Now we’ll examine how Rapid7’s modest quarterly...
NYSE:BNT
NYSE:BNTInsurance

Brookfield Wealth Solutions (BNT) Margin Compression Challenges Bullish Earnings Growth Narrative

Brookfield Wealth Solutions (BNT) has wrapped up FY 2025 with Q4 revenue of about US$3.1b and basic EPS of roughly US$0.03, capping a year in which trailing 12 month revenue came in at US$11.6b and EPS at US$2.49. The company has seen quarterly revenue move between US$2.6b and US$3.1b across FY 2025, while basic EPS swung from a loss of US$0.90 in Q1 2025 to US$1.89 in Q3 2025 and US$0.03 in Q4 2025. This puts the focus on how consistently those earnings can convert into lasting...
NYSE:AEM
NYSE:AEMMetals and Mining

Agnico Eagle Mines (NYSE:AEM) Margin Surge To 37.5% Tests Bearish Cost Narratives

Agnico Eagle Mines (NYSE:AEM) FY 2025 earnings snapshot Agnico Eagle Mines (NYSE:AEM) closed out FY 2025 with Q4 revenue of US$3.6 billion and basic EPS of US$3.04, while trailing twelve month revenue reached US$11.9 billion and EPS came in at US$8.89, alongside a 135.4% rise in earnings over the last year. Over recent periods, the company has seen revenue move from US$8.3 billion and EPS of US$3.79 on a trailing basis at the end of 2024 to US$11.9 billion and EPS of US$8.89 by Q4 2025, with...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Is It Time To Reassess Exact Sciences (EXAS) After The US$105 Abbott Offer?

If you are wondering whether Exact Sciences is still worth your attention at current prices, the key question is how its market value compares with what the business may be worth on paper. The stock last closed at US$103.24, with returns of 0.1% over 7 days, 1.0% over 30 days, 1.5% year to date, 109.4% over 1 year, 62.6% over 3 years, and a 30.2% decline over 5 years. Recent news around Exact Sciences has focused on its position in cancer diagnostics and how its core products fit into...
NasdaqGS:KPTI
NasdaqGS:KPTIBiotechs

Karyopharm Therapeutics (KPTI) TTM US$196 Million Loss Tests Bullish Profitability Narratives

Karyopharm Therapeutics FY 2025 earnings snapshot Karyopharm Therapeutics (KPTI) closed FY 2025 with Q4 revenue of US$34.1 million and a basic EPS loss of US$5.68, alongside a net loss of US$102.2 million. On a trailing twelve month basis, EPS stood at a loss of US$17.93 on revenue of US$146.1 million and a net loss of US$196.0 million. The company has reported quarterly revenue ranging from US$30.0 million to US$44.0 million over the past year, with basic EPS losses between US$2.77 and...